Drug
Faricimab Injection
Faricimab Injection is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting1
Enrolling by invitation1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 42 (66.7%)
Trials by Status
recruiting133%
enrolling_by_invitation133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_2
Intravitreal Faricimab in Patients With Refractory Macular Edema
NCT07093385
recruitingphase_4
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
NCT06875245
enrolling_by_invitationphase_4
Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
NCT06191094
Clinical Trials (3)
Showing 3 of 3 trials
NCT07093385Phase 2
Intravitreal Faricimab in Patients With Refractory Macular Edema
NCT06875245Phase 4
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
NCT06191094Phase 4
Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3